IBRXImmunityBio, Inc.

$8B

Q2 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$4,000-71.4% YoY

Gross Profit

$4,000100.0% margin

Operating Income

-$28M-693725.0% margin

Net Income

-$28M-693300.0% margin

EPS (Diluted)

$-0.09

QoQ Revenue Growth

-20.0%

Cash Flow

Operating Cash Flow

-$16M

Free Cash Flow

-$19M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$211M

Total Liabilities

$30M

Stockholders' Equity

$182M

Cash & Equivalents

$16M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4,000	$14,000	-71.4%
Gross Profit	$4,000	$14,000	-71.4%
Operating Income	-$28M	-$23M	-18.5%
Net Income	-$28M	-$23M	-18.3%

IBRX Q2 2018 Earnings — ImmunityBio, Inc. Revenue & Financial Results | Market Cap Arena